Scienture Added Arbli to Pediatric Medical Centers
The oral hypertension suspension has been adopted by three U.S. pediatric academic medical centers.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should pharmaceutical companies prioritize developing specialized formulations for patients with difficulty swallowing tablets?
Scienture Holdings Inc. has secured the addition of Arbli, an oral suspension of losartan potassium, to the formularies of three pediatric academic medical centers. The medication is designed for patients six years and older, providing a pre-mixed alternative to conventional tablets.
Why it matters
The medication assists pediatric patients who experience difficulty swallowing traditional tablets, offering a flexible dosing option. This move reflects a broader effort to expand access within institutional settings for those requiring specialized hypertension treatment.
Scienture expanded payer coverage by 12.5 million lives in the second quarter of 2026. The broader U.S. losartan market generates approximately $219 million in annual sales across 72 million prescriptions.
The players
Scienture Holdings Inc.
Scienture Holdings Inc. is a pharmaceutical company focused on expanding access to specialized medication formulations.
The details
Arbli provides a pre-mixed treatment at a concentration of 10 mg/mL, which eliminates the need for extemporaneous pharmacy compounding. The company plans to pursue additional hospital and institutional formulary opportunities in pediatric healthcare settings across the United States.
Timeline
October 2, 2026: Scienture announced the new hospital adoptions.
April 2026: Market data for the U.S. losartan market was generated.
Q2 2026: The company expanded payer coverage and commercial access.
Market Landscape
The adoption of Arbli reflects a strategic effort to penetrate the highly competitive $219 million U.S. losartan market. By securing formulary status, Scienture positions its liquid formulation to compete against established tablet-based therapies.
Patients and caregivers at these medical centers can access a pre-mixed, flexible dosing treatment without requiring pharmacy compounding. This simplification may reduce wait times for patients starting hypertension therapy.
The takeaway
The shift toward pre-mixed suspensions in pediatric care prioritizes patient compliance and medication safety. Specialized formulations like Arbli simplify the administration of maintenance drugs for younger patients.
Further reading
Learn more about the latest developments in Healthcare.
Live Poll
Should pharmaceutical companies prioritize developing specialized formulations for patients with difficulty swallowing tablets?
